Chromium for Lipid Profile

Table of Contents

1. Why Insulin Resistance Drives Dyslipidemia
2. The Press 1990 UC Davis Trial
3. Total Cholesterol Effects
4. Low-Density Lipoprotein Cholesterol and the Low-Density Lipoprotein Receptor
5. High-Density Lipoprotein Cholesterol and Reverse Transport
6. Triglycerides and Very-Low-Density Lipoprotein Metabolism
7. Hepatic Mechanism: HMG-CoA, ApoB, Very-Low-Density Lipoprotein Secretion
8. Free Fatty Acid Flux from Adipose Tissue
9. Meta-Analyses in Type 2 Diabetes Populations
10. Combination With Statins, Niacin, and Ezetimibe
11. Key Research Papers
12. Connections
13. Featured Videos

Why Insulin Resistance Drives Dyslipidemia

Dyslipidemia is one of the diagnostic criteria for metabolic syndrome (elevated triglycerides above 150 mg/dL, reduced high-density lipoprotein below 40 mg/dL in men or 50 mg/dL in women), and the lipid abnormalities of metabolic syndrome are mechanistically linked to insulin resistance rather than to dietary cholesterol intake. Understanding why insulin resistance produces a characteristic lipid pattern is essential to understanding why an insulin-sensitizing agent like chromium produces predictable directional effects on the lipid panel.

Insulin normally has three lipid-relevant actions:

1. Suppresses hormone-sensitive lipase (HSL) in adipose tissue — in the fed state, insulin shuts down adipocyte lipolysis, reducing free fatty acid (FFA) release into the bloodstream. In insulin-resistant adipose tissue, this suppression fails, and FFA flux remains chronically elevated.
2. Suppresses hepatic very-low-density lipoprotein secretion — insulin normally signals the liver to package fatty acids into triglycerides for storage rather than for export. In insulin-resistant liver, the elevated FFA flux from adipose tissue plus the failure of insulin's suppressive signal drives excess very-low-density lipoprotein production. Very-low-density lipoprotein particles are the triglyceride-carrying lipoprotein, so very-low-density lipoprotein excess shows up clinically as hypertriglyceridemia.
3. Activates lipoprotein lipase (LPL) in muscle and adipose capillary endothelium — insulin upregulates LPL, the enzyme that hydrolyzes triglyceride from circulating very-low-density lipoprotein and chylomicrons, allowing fatty acid uptake into tissues. In insulin resistance, LPL activity drops, slowing the clearance of triglyceride-rich particles and prolonging postprandial hypertriglyceridemia.

The downstream cascade produces the characteristic "atherogenic dyslipidemia" of metabolic syndrome: elevated triglycerides, reduced high-density lipoprotein cholesterol (because high-density lipoprotein is metabolically consumed in cholesterol-ester transfer protein-mediated exchange with triglyceride-rich particles), and a shift toward small dense low-density lipoprotein particles (which are more atherogenic than large buoyant low-density lipoprotein even at the same low-density lipoprotein-cholesterol concentration). Crucially, this pattern occurs even with normal dietary cholesterol intake — it is driven by impaired insulin signaling, not by what is on the dinner plate.

By improving insulin sensitivity at the receptor level, chromium addresses the upstream driver of all three lipid abnormalities simultaneously. This is mechanistically why the Press trial and subsequent confirmatory studies observe a coordinated improvement in total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides — they are all downstream of the same restored insulin signal.

Back to Table of Contents

The Press 1990 UC Davis Trial

Raymond I. Press, Joseph Geller, and Gary W. Evans published the most-cited chromium-and-lipids trial in the Western Journal of Medicine in 1990. The design was rigorous for its era: 28 free-living adults with elevated baseline total cholesterol (above 200 mg/dL) were randomized in a double-blind, placebo-controlled, crossover design. Each subject received 200 mcg/day of chromium (as chromium chloride) for 42 days, separated by a 14-day washout, with each subject acting as their own placebo control.

The results, after pooled analysis of the chromium-on-treatment periods:

• Total cholesterol — reduced from a mean of 270 mg/dL to 250 mg/dL (approximately 7% reduction)
• Low-density lipoprotein cholesterol — reduced from approximately 175 mg/dL to 157 mg/dL (approximately 10% reduction)
• High-density lipoprotein cholesterol — modest elevation, on the order of 1–3 mg/dL (smaller effect, more variable across subjects)
• Apolipoprotein B (ApoB) — reduced, consistent with reduced low-density lipoprotein particle number
• Apolipoprotein A-I (ApoA-I) — modest elevation, consistent with increased high-density lipoprotein particle number

The Press trial was important for several reasons. First, it used the obsolete chromium chloride form (lower bioavailability than picolinate or polynicotinate), yet still produced clinically meaningful lipid effects — suggesting the picolinate/polynicotinate forms, which absorb several times more efficiently, would produce at least equivalent effects at equivalent doses. Second, it predates the era of widespread statin use, so the effects observed were due solely to chromium rather than to a chromium-statin interaction. Third, the crossover design eliminated between-subject variability as a confounder, increasing statistical power despite a small sample.

Press's interpretation was that chromium acted through insulin-receptor sensitization to reduce hepatic cholesterol synthesis (HMG-CoA reductase activity is partially insulin-regulated) and to enhance hepatic low-density lipoprotein receptor expression. The mechanistic detail has been refined in subsequent decades, but Press's broad framing has held up: chromium improves lipids primarily by restoring normal insulin signaling at the liver.

Subsequent replication has been variable. Some Western trials in diabetic populations have replicated lipid effects of similar magnitude (Yin and Phung 2015 meta-analysis, Suksomboon 2014 meta-analysis); other trials have found smaller or non-significant effects. The pattern across this literature is that lipid effects are clearest in subjects with elevated baseline values and concurrent insulin resistance — consistent with the upstream-driver interpretation.

Back to Table of Contents

Total Cholesterol Effects

Total cholesterol is a coarse summary measure that confounds the underlying lipid particles (low-density lipoprotein, high-density lipoprotein, very-low-density lipoprotein remnants, lipoprotein(a)). Modern lipidology has largely moved away from emphasizing total cholesterol in favor of low-density lipoprotein-cholesterol and ApoB. That said, chromium supplementation in hyperlipidemic and diabetic populations consistently produces total cholesterol reductions on the order of 10–25 mg/dL, with effect magnitude tracking baseline severity.

The mechanism is partly low-density lipoprotein-mediated (covered below) and partly the reduction in very-low-density lipoprotein remnant particles. Very-low-density lipoprotein remnants contribute to measured total cholesterol but are not separately quantified on a standard lipid panel; they are atherogenic. Insulin sensitization reduces very-low-density lipoprotein secretion from the liver, reduces postprandial very-low-density lipoprotein retention, and thereby reduces very-low-density lipoprotein contribution to total cholesterol.

For clinical purposes, total cholesterol response to chromium is a reasonable summary marker but should not be the only outcome tracked. A fuller assessment requires the calculated low-density lipoprotein (or measured ApoB), high-density lipoprotein, and triglycerides, ideally with the non-HDL cholesterol value as a single integrated measure of atherogenic particle burden.

Back to Table of Contents

Low-Density Lipoprotein Cholesterol and the Low-Density Lipoprotein Receptor

Low-density lipoprotein cholesterol is the cardiovascular-disease-relevant lipid measure (along with ApoB). Hepatic low-density lipoprotein receptor (LDLR) expression is the rate-limiting step in clearance of circulating low-density lipoprotein particles. The low-density lipoprotein receptor is regulated by intracellular cholesterol concentration (low intracellular cholesterol upregulates LDLR via SREBP-2) and, separately, by insulin signaling. Insulin acutely upregulates LDLR mRNA and protein in hepatocytes, increasing the rate at which the liver removes low-density lipoprotein from the bloodstream.

In insulin resistance, hepatic LDLR upregulation by insulin is impaired, slowing low-density lipoprotein clearance and elevating circulating low-density lipoprotein concentrations. Chromium's restoration of insulin signaling at the liver restores LDLR expression toward normal, increasing low-density lipoprotein clearance. The clinical signature is reduced low-density lipoprotein cholesterol concentration; the underlying mechanism is increased low-density lipoprotein-receptor-mediated removal.

There is a useful conceptual symmetry here with statin drugs. Statins (HMG-CoA reductase inhibitors) work by reducing intracellular hepatic cholesterol synthesis, which depletes intracellular cholesterol, activates SREBP-2, and upregulates LDLR. The endpoint is the same as chromium — more LDLR on the hepatocyte surface — but via a different upstream mechanism. This is why combining chromium with a statin sometimes produces additive lipid lowering in clinical practice (though the additive effect is small relative to the statin effect alone).

Chromium also appears to modestly reduce intestinal cholesterol absorption, possibly through effects on NPC1L1 expression (the target of ezetimibe), though this evidence is preclinical and the magnitude is small. The dominant low-density lipoprotein mechanism remains hepatic LDLR upregulation.

Back to Table of Contents

High-Density Lipoprotein Cholesterol and Reverse Transport

High-density lipoprotein is the cardioprotective lipoprotein, responsible for "reverse cholesterol transport" — the removal of cholesterol from peripheral tissues (including arterial-wall foam cells) back to the liver for biliary excretion. Higher high-density lipoprotein is associated with lower cardiovascular risk in observational studies, although pharmacological high-density lipoprotein elevation (CETP inhibitors, niacin in some studies) has not produced reliable cardiovascular benefit in randomized trials, suggesting the association is partly reverse-causation from healthy lifestyle.

Chromium's effects on high-density lipoprotein are smaller and less consistent than its effects on low-density lipoprotein and triglycerides. Most trials report modest high-density lipoprotein elevation in the range of 1–5 mg/dL; some find no significant effect. The mechanism, where present, appears to be reduction in CETP-mediated transfer of cholesteryl esters from high-density lipoprotein to triglyceride-rich particles. When circulating triglyceride-rich particles drop (chromium's triglyceride effect), CETP has fewer substrate particles, and high-density lipoprotein retains more of its cholesteryl ester cargo, manifesting as higher high-density lipoprotein cholesterol on the lipid panel.

This is a downstream-of-triglyceride effect rather than a direct high-density lipoprotein-elevating mechanism, which is consistent with the observation that high-density lipoprotein responses to chromium track triglyceride responses across studies. In trials where triglyceride drops are large, high-density lipoprotein elevations tend to be larger; in trials with minimal triglyceride change, high-density lipoprotein change is minimal.

The clinical implication: high-density lipoprotein elevation should not be the primary expected benefit of chromium supplementation. Patients hoping for high-density lipoprotein elevation should focus on aerobic exercise (largest reliable high-density lipoprotein-elevating intervention), weight loss, and moderation of carbohydrate intake.

Back to Table of Contents

Triglycerides and Very-Low-Density Lipoprotein Metabolism

Triglyceride reduction is the most consistent and largest-magnitude lipid effect of chromium supplementation in insulin-resistant populations. Pooled meta-analyses report mean triglyceride reductions of 15–30 mg/dL in diabetic subjects, with larger effects in subjects with higher baseline triglycerides. This is mechanistically expected because triglycerides are the lipid pool most directly affected by insulin signaling at the liver and adipose tissue.

The triglyceride-lowering mechanism operates at three levels:

• Reduced hepatic very-low-density lipoprotein secretion — restored insulin signaling at the liver suppresses ApoB-100 secretion and very-low-density lipoprotein packaging. Fewer triglyceride-loaded very-low-density lipoprotein particles enter the circulation.
• Reduced substrate supply to liver — improved insulin signaling at adipose tissue suppresses hormone-sensitive lipase, reducing FFA flux to the liver. Less FFA arriving at the liver means less substrate for triglyceride synthesis.
• Increased lipoprotein lipase activity at peripheral tissues — restored insulin signaling at muscle and adipose capillary endothelium upregulates LPL, accelerating hydrolysis and clearance of triglyceride-rich particles from the bloodstream.

The result is reduced rate of very-low-density lipoprotein entry and increased rate of triglyceride-rich particle clearance — a coordinated reduction in circulating triglyceride concentration. The magnitude in well-conducted trials is comparable to what can be achieved with fish oil at 2–4 g/day of combined eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) (also a triglyceride-lowering intervention, but via a different mechanism).

For patients with severe hypertriglyceridemia (above 500 mg/dL, where pancreatitis risk becomes significant), chromium is not adequate as monotherapy — fibrate drugs (gemfibrozil, fenofibrate) or prescription omega-3 fatty acid esters (icosapent ethyl) are first-line. For mild-moderate hypertriglyceridemia (150–500 mg/dL) in the context of metabolic syndrome or type 2 diabetes, chromium is a reasonable adjunctive intervention alongside lifestyle modification.

Back to Table of Contents

Hepatic Mechanism: HMG-CoA, ApoB, Very-Low-Density Lipoprotein Secretion

Zooming in on the hepatocyte: the liver is the central organ of lipid metabolism and the principal site of chromium's lipid-modulating effects. Three hepatic processes are particularly relevant:

• HMG-CoA reductase — the rate-limiting enzyme of cholesterol biosynthesis. HMG-CoA reductase is regulated by intracellular cholesterol concentration (sterol-mediated feedback), by SREBP-2 (the master transcription factor for cholesterol synthesis genes), and partially by insulin (insulin signaling has modest direct and indirect effects on hepatic HMG-CoA reductase activity). Chromium's contribution here is small relative to statin effect but is the proposed partial mechanism for the total cholesterol reduction observed in the Press 1990 trial.
• Apolipoprotein B-100 (ApoB-100) — the obligate structural protein of very-low-density lipoprotein and low-density lipoprotein particles. Each very-low-density lipoprotein or low-density lipoprotein particle contains exactly one ApoB-100 molecule, so ApoB concentration directly reflects atherogenic particle number. ApoB-100 secretion from hepatocytes is suppressed by insulin in the normal state; in insulin resistance, this suppression fails, and ApoB-100 secretion rises. Chromium's restoration of hepatic insulin signaling restores partial ApoB-100 secretion suppression. Several studies measure ApoB as a more sensitive secondary endpoint and report reductions consistent with the underlying mechanism.
• Very-low-density lipoprotein packaging and secretion — the assembly of very-low-density lipoprotein particles in the hepatocyte endoplasmic reticulum requires ApoB-100 plus triglyceride plus cholesteryl ester, and the rate-limiting step is microsomal triglyceride transfer protein (MTP). Insulin signaling represses MTP transcription and reduces ApoB-100 stability, reducing the overall very-low-density lipoprotein output. Restored insulin signaling from chromium supplementation translates to reduced very-low-density lipoprotein output, which is the proximate cause of the observed triglyceride reduction.

The integrated picture is that chromium acts primarily at the hepatocyte, primarily through restoration of insulin signaling, and the lipid-panel effects are downstream consequences. This is mechanistically distinct from drugs that act on lipid metabolism enzymes directly (statins, fibrates, ezetimibe, PCSK9 inhibitors) and explains why chromium's effects are modest in magnitude but broad in spectrum (touching low-density lipoprotein, high-density lipoprotein, and triglycerides simultaneously) rather than focused and dramatic on a single lipid parameter.

Back to Table of Contents

Free Fatty Acid Flux from Adipose Tissue

The other major chromium-relevant lipid process is adipose tissue free fatty acid release. In the fed state, insulin should suppress adipocyte lipolysis by phosphorylating hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) into their inactive forms. In insulin-resistant adipose tissue, this suppression fails, and FFA continues to flow out of adipocytes even in the postprandial state when it should be stored as triglyceride.

This chronic FFA over-supply has downstream consequences: hepatic uptake of excess FFA drives very-low-density lipoprotein overproduction (as described above), muscle uptake of excess FFA drives intramyocellular lipid accumulation and worsening of muscle insulin resistance (lipotoxicity), and pancreatic beta-cell uptake of excess FFA contributes to lipotoxic beta-cell dysfunction.

Chromium's restoration of insulin signaling at adipose tissue tends to suppress inappropriate lipolysis and reduce FFA flux. This is a slow effect that builds over weeks of supplementation rather than acutely; the clinical signature is reduced fasting FFA concentration and reduced 24-hour FFA AUC.

Reducing FFA flux also relieves the secondary insulin resistance at muscle and liver that FFA over-supply was inducing. This is one mechanism behind the observation that long-term chromium supplementation produces progressively larger effects on glucose disposal — the early benefit is direct insulin-receptor amplification, but a slower-developing benefit is reversal of lipotoxic insulin resistance at distant tissues.

Back to Table of Contents

Meta-Analyses in Type 2 Diabetes Populations

Three meta-analyses are the dominant evidence summary for chromium effects on lipids in type 2 diabetes populations:

• Balk et al. 2007 (Diabetes Care) — pooled 41 trials including diabetic and non-diabetic subjects. In diabetic subjects, found statistically significant reductions in fasting glucose, hemoglobin A1c (HbA1c), and triglycerides; low-density lipoprotein and high-density lipoprotein effects were not statistically significant in the pooled analysis but were directionally consistent. This is the most widely cited chromium meta-analysis.
• Suksomboon, Poolsup, Yuwanakorn 2014 (J Clin Pharm Ther) — pooled 25 trials of chromium in diabetes. Found significant reductions in fasting glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein, and triglycerides, plus a small but statistically significant high-density lipoprotein increase. Effect sizes were modest but directionally consistent across the lipid panel. The triglyceride effect was the largest in absolute magnitude, consistent with the upstream mechanistic story.
• Yin and Phung 2015 (Nutrition Journal) — pooled 22 trials. Found significant hemoglobin A1c reduction in patients with poor baseline glycemic control. Lipid effects were directionally consistent with prior meta-analyses but smaller in magnitude.

Across these meta-analyses, the consistent pattern is: chromium produces measurable improvements in the lipid panel of patients with type 2 diabetes, with effects on triglycerides being the most reliable, effects on low-density lipoprotein and total cholesterol being moderate and consistent, and effects on high-density lipoprotein being smaller and less consistent. The magnitude of effect is modest in absolute terms (a few mg/dL on each parameter) but cumulative across the panel.

Critical caveats from the meta-analyses: heterogeneity across included trials is substantial; not every individual trial replicates the pooled effect; chromium form (picolinate vs polynicotinate vs chloride) was not always specified in older trials; dose ranged across two orders of magnitude (16 mcg/day to 1,000 mcg/day); and many included trials had modest sample sizes and follow-up durations.

Back to Table of Contents

Combination With Statins, Niacin, and Ezetimibe

For most adult patients with dyslipidemia warranting pharmacologic treatment, statin therapy (atorvastatin, rosuvastatin, simvastatin, pravastatin) is first-line. Chromium is not a substitute for statins in patients with significant cardiovascular risk — the magnitude of low-density lipoprotein reduction with chromium (10–15% in well-responding studies) is several-fold smaller than the low-density lipoprotein reduction achievable with moderate-intensity statin therapy (30–50% low-density lipoprotein reduction).

Chromium has been studied as an adjunct to statin therapy in a small number of trials. The pattern observed is additive but not synergistic: combination produces incremental low-density lipoprotein and triglyceride reduction beyond statin alone, but the magnitude of additive benefit is small (typically 5–10 mg/dL further low-density lipoprotein reduction). For patients already at low-density lipoprotein goal on a statin, adding chromium is unlikely to be clinically useful. For patients close to but not at goal, adding chromium is a reasonable low-cost intervention alongside diet modification.

The combination with niacin (vitamin B3) is interesting because chromium polynicotinate is structurally a chromium-niacin complex, and niacin itself is a lipid-modulating intervention (reduces low-density lipoprotein and triglycerides, raises high-density lipoprotein at gram-per-day doses). Whether chromium polynicotinate produces lipid effects beyond what its niacin content alone would predict is an unresolved question. Most clinical trials of chromium polynicotinate use doses providing only milligrams of niacin (well below the gram doses needed for niacin's independent lipid effect), so the lipid effects observed are likely due to the chromium rather than the niacin moiety. Therapeutic-dose niacin (1–3 g/day) plus chromium picolinate is a reasonable combination for patients who tolerate niacin and want broad lipid panel improvement; this combination should be physician-supervised because niacin can elevate uric acid, blood glucose, and liver enzymes.

Ezetimibe (Zetia) inhibits intestinal cholesterol absorption via NPC1L1. There is no published clinical trial of chromium-ezetimibe combination; the two interventions act through different mechanisms (gut-luminal absorption inhibition vs hepatic insulin sensitization) and should be additive. Whether the additive effect is clinically meaningful is untested.

PCSK9 inhibitors (alirocumab, evolocumab) are injectable monoclonal antibodies for refractory hypercholesterolemia or familial hypercholesterolemia. Chromium has not been studied as an adjunct to PCSK9 therapy. The mechanisms are independent and additive effects would be expected, but the clinical importance is small relative to the dominant PCSK9 effect.

This content is provided for informational purposes only and does not constitute medical advice. Patients with elevated cardiovascular risk should discuss lipid management with their physician. Chromium is not a substitute for indicated lipid-lowering medications.

Back to Table of Contents

Key Research Papers

1. Press RI, Geller J, Evans GW (1990). The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. Western Journal of Medicine 152(1):41-45. — PubMed PMID: 2408233
2. Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007). Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 30(8):2154-2163. — DOI: 10.2337/dc06-0996. — doi:10.2337/dc06-0996
3. Suksomboon N, Poolsup N, Yuwanakorn A (2014). Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. Journal of Clinical Pharmacy and Therapeutics 39(3):292-306. — PubMed PMID: 24635480
4. Yin RV, Phung OJ (2015). Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutrition Journal 14:14. — PubMed PMID: 25971249
5. Abraham AS, Brooks BA, Eylath U (1992). The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 41(7):768-771. — PubMed PMID: 1619996
6. Riales R, Albrink MJ (1981). Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. American Journal of Clinical Nutrition 34(12):2670-2678. — PubMed PMID: 7032273
7. Cheng N, Zhu X, Shi H, et al. (1999). Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. Journal of Trace Elements in Experimental Medicine 12:55-60. — PubMed
8. Ngala RA, Awe MA, Nsiah P (2018). The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. PLoS ONE 13(7):e0197977. — PubMed PMID: 29975702
9. Asbaghi O, Naeini F, Ashtary-Larky D, et al. (2021). Effects of chromium supplementation on lipid profile in patients with type 2 diabetes: a systematic review and dose-response meta-analysis of randomized controlled trials. Journal of Trace Elements in Medicine and Biology 66:126741. — PubMed PMID: 33813266
10. Hua Y, Clark S, Ren J, Sreejayan N (2012). Molecular mechanisms of chromium in alleviating insulin resistance. Journal of Nutritional Biochemistry 23(4):313-319. — PubMed PMID: 22423897
11. Ginsberg HN, Zhang YL, Hernandez-Ono A (2005). Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research 36(3):232-240. — PubMed PMID: 15925013
12. Adams JF, Engstrom A (2000). Helping consumers achieve recommended intakes of whole grain foods. Journal of the American College of Nutrition 19(3):339S-344S. — PubMed

PubMed Topic Searches

1. PubMed: Chromium and lipid profile meta-analyses
2. PubMed: Chromium picolinate and triglycerides
3. PubMed: Chromium and LDL receptor
4. PubMed: Chromium and HDL
5. PubMed: Insulin resistance dyslipidemia mechanism

Back to Table of Contents

Connections

• All Minerals
• Chromium Overview
• Chromium Benefits Hub
• Chromium for Blood Sugar
• Chromium for Insulin Sensitivity
• Chromium for Weight Management
• Cardiovascular Disease
• Atherosclerosis
• Metabolic Syndrome
• Type 2 Diabetes
• Niacin / Vitamin B3
• Lipid Panel
• Omega-3 Fatty Acids
• Berberine
• Cinnamon
• Magnesium
• Insulin Resistance
• Blood Sugar
• Obesity
• Deficiency
• Toxicity
• History

Back to Table of Contents

Featured Videos